Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Mississippi
Clinical trial register · United States · industry-sponsored

Clinical Trials in Mississippi, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9132 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 11 Oct 2026, 03:16 UTC
9132
Studies in scope
industry-sponsored, all four open statuses
4964
Recruiting now
open to new participants
2194
Lead sponsors
across recruiting studies
Top states
California 5299 Florida 4438 Illinois 2485 Georgia 2364 Arizona 2242
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Merck Sharp & Dohme LLC7 Regeneron Pharmaceuticals5 Pfizer5 Zimmer Biomet4 AbbVie4
State
California5299 Florida4438 Illinois2485 Georgia2364 Arizona2242
All 51 states
Target enrolment
to

Trials with a site in Mississippi

136 of 9132 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Biojiva LLC
Phase 1/2
152
Arizona, Mississippi, Nevada, Ohio, Texas, Utah, Washington
2026-09-29
Not yet open
Mynerva Inc.
Not applicable
100
Mississippi
2026-09-18
Recruiting
Bristol-Myers Squibb
Phase 2
160
District of Columbia, Georgia, Kentucky, Maryland, Mississippi, Nebraska, New York, Ohio
2026-09-10
Recruiting
A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07845487Ulcerative Colitis (UC), Severe Ulcerative Colitis, Moderate Ulcerative Colitis
DrugPALI-2108
Palisade Bio
Phase 2
204
Arizona, California, Connecticut, Florida, Illinois, Louisiana, Mississippi, Missouri
2026-08-28
Recruiting
Merck Sharp & Dohme LLC
Phase 3
960
California, Colorado, Connecticut, Florida, Kansas, Maryland, Mississippi, New Jersey
2026-08-27
Recruiting
Agios Pharmaceuticals, Inc.
Phase 3
159
Indiana, Michigan, Mississippi
2026-07-21
Recruiting
Axsome Therapeutics, Inc.
Phase 3
468
Alabama, Arkansas, California, Florida, Georgia, Kentucky, Massachusetts, Mississippi
2026-07-06
Recruiting
Axsome Therapeutics, Inc.
Phase 3
468
Alabama, Arkansas, California, Florida, Georgia, Kentucky, Massachusetts, Mississippi
2026-06-25
Recruiting
Centessa Pharmaceuticals (UK) Limited
Phase 2/3
222
Alabama, Colorado, Florida, Georgia, Mississippi, North Carolina, Ohio, South Carolina
2026-05-29
Recruiting
Pfizer
Phase 4
400
California, Florida, Indiana, Massachusetts, Michigan, Minnesota, Mississippi, Nevada
2026-05-28
Recruiting
NuScience Medical Biologics, LLC
Not applicable
122
Louisiana, Mississippi
2026-05-14
Recruiting
Theranica
Not applicable
100
Delaware, Mississippi, New York, Virginia
2026-05-04
Recruiting
Boehringer Ingelheim
Phase 2
405
California, Colorado, Florida, Michigan, Mississippi, Montana, North Carolina, Ohio
2026-04-20
Recruiting
EVERO Drug-coated Balloon (DCB) Randomized Trial
NCT07144150Peripheral Vascular Disease, Peripheral Arterial Disease
Cook Research Incorporated
Not applicable
410
Connecticut, Florida, Iowa, Michigan, Mississippi, New Jersey, South Carolina, Texas
2026-04-17
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
150
California, Florida, Illinois, Iowa, Mississippi, Nebraska, New Jersey, New York
2026-04-16
Active, closed
Veru Inc.
Phase 2
239
Arizona, Florida, Louisiana, Maryland, Mississippi, New York, North Carolina, Texas
2026-03-26
Not yet open
Invero Pharma, Inc.
Phase 3
1,436
Connecticut, Florida, Mississippi, Nebraska, New York, Ohio, Tennessee, Texas
2026-03
Recruiting
A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults
NCT07425574Stargardt Disease, Stargardt Macular Dystrophy, Stargardt-like Macular Dystrophy
Astellas Pharma Global Development, Inc.
Observational
90
Arizona, California, Florida, Illinois, Michigan, Mississippi, North Carolina, Ohio
2026-02-20
Recruiting
CSL Behring
Phase 2
63
Arkansas, California, Florida, Georgia, Maryland, Mississippi, New York, Ohio
2026-02-02
Recruiting
Exciva GmbH
Phase 2/3
300
California, Indiana, Mississippi, Missouri, New York, Ohio, Oregon, Vermont
2026-02-02
Recruiting
Navigator Medicines, Inc.
Phase 2
150
Arizona, Florida, Kentucky, Massachusetts, Mississippi, New Hampshire, New York
2026-01-05
Recruiting
Draig Therapeutics Ltd
Phase 2
300
Arkansas, California, Florida, Georgia, Maryland, Massachusetts, Mississippi, Nevada
2025-12-16
Recruiting
Neurocrine Biosciences
Phase 3
560
California, Florida, Georgia, Massachusetts, Mississippi, New Jersey, New York, Texas
2025-12-16
Recruiting
Omeza, LLC
Not applicable
180
Illinois, Louisiana, Mississippi, Ohio
2025-12-04
Active, closed
Arthrosi Therapeutics
Phase 2
15
Florida, Mississippi, North Carolina, Pennsylvania, Texas, Washington
2025-12-03
Recruiting
Generate Biomedicines
Phase 3
786
California, Colorado, Florida, Georgia, Illinois, Maryland, Michigan, Mississippi
2025-12-03
Recruiting
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
NCT07169851Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms
Eli Lilly and Company
Phase 2
204
California, Colorado, Florida, Georgia, Illinois, Indiana, Mississippi, New York
2025-11-28
Recruiting
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
NCT07284667Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant
ACADIA Pharmaceuticals Inc.
Phase 2
153
Alabama, California, Colorado, Florida, Massachusetts, Mississippi, Missouri, Nebraska
2025-11-14
Recruiting
Agitated Solutions, Inc.
Phase 3
300
Illinois, Minnesota, Mississippi, New York, Wisconsin
2025-11-05
Recruiting
Novartis Pharmaceuticals
Phase 2
165
Mississippi, New Jersey, New York, North Carolina, Utah, Washington
2025-10-28
Recruiting
NuScience Medical Biologics, LLC
Not applicable
132
Louisiana, Mississippi, New York
2025-10-16
Recruiting
NuScience Medical Biologics, LLC
Not applicable
132
Louisiana, Mississippi, Pennsylvania
2025-10-06
Recruiting
A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO
NCT07205887Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
DrugsRestoret·Aflibercept
EyeBiotech Ltd.
Phase 2
160
Arizona, California, Colorado, Florida, Illinois, Maryland, Mississippi, New Jersey
2025-09-12
Recruiting
Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare
NCT07145229Acute Gouty Arthritis, Gout Flare, Gout Flares, Acute Gout Flare
DrugsABP-745 A·ABP-745 B·Colchicine
Atom Therapeutics Co., Ltd
Phase 2
380
Arizona, California, Georgia, Illinois, Iowa, Louisiana, Maryland, Mississippi
2025-08-26
Recruiting
AstraZeneca
Phase 3
250
California, Connecticut, Illinois, Maryland, Massachusetts, Michigan, Minnesota, Mississippi
2025-08-07
Active, closed
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
NCT07044297Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
DrugMK-8527
Merck Sharp & Dohme LLC
Phase 3
4,390
Alabama, California, District of Columbia, Florida, Georgia, Illinois, Louisiana, Mississippi
2025-07-31
Recruiting
Bristol-Myers Squibb
Phase 3
586
California, Colorado, Florida, Illinois, Indiana, Massachusetts, Michigan, Mississippi
2025-07-21
Recruiting
Neurocrine Biosciences
Phase 3
600
Arkansas, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Mississippi
2025-07-11
Recruiting
Biocomposites Ltd
Phase 2
60
Arizona, Illinois, Michigan, Mississippi, Missouri, Nebraska, New Jersey, New York
2025-06-15
Recruiting
A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
NCT06933472Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease), Dialysis
Alebund Pharmaceuticals
Phase 3
264
California, Colorado, Connecticut, Florida, Georgia, Louisiana, Mississippi, New Mexico
2025-06-13
Recruiting
Bristol-Myers Squibb
Phase 3
274
Arkansas, California, Florida, Georgia, Illinois, Maryland, Mississippi, Missouri
2025-06-13
Recruiting
PGP Health
Not applicable
20
Florida, Illinois, Mississippi
2025-05-21
Recruiting
MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels
NCT06271590Coronary Artery Disease, Native Coronary Artery Stenosis, Cardiovascular Diseases
Concept Medical Inc.
Not applicable
1,605
Arizona, California, Florida, Georgia, Illinois, Mississippi, New Jersey, New York
2025-05-20
Recruiting
Vanda Pharmaceuticals
Phase 3
400
Arkansas, California, Florida, Georgia, Illinois, Mississippi, Missouri, Nevada
2025-05-14
Recruiting
Biogen
Phase 3
454
Arkansas, California, Florida, Georgia, Massachusetts, Michigan, Mississippi, Missouri
2025-05-08
Recruiting
SPYRAL GEMINI Pilot Study
NCT06907147Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases
Medtronic Vascular
Not applicable
175
California, Florida, Georgia, Massachusetts, Michigan, Mississippi, Nevada, New Jersey
2025-05-01
Active, closed
Pivotal Study of Voro Urologic Scaffold
NCT06873581Radical Prostatectomy, Stress Urinary Incontinence (SUI)
Levee Medical, Inc.
Phase 3
266
Arizona, California, Florida, Illinois, Indiana, Maryland, Mississippi, New York
2025-04-18
Recruiting
W.L.Gore & Associates
Not applicable
180
Arizona, California, Florida, Illinois, Kansas, Maryland, Michigan, Mississippi
2025-04-09
Active, closed
Sanofi Pasteur, a Sanofi Company
Phase 3
1,268
California, Florida, Georgia, Iowa, Kentucky, Mississippi, Nebraska, New York
2025-02-28
Recruiting
AbbVie
Phase 3
420
Alabama, Arkansas, California, Florida, Indiana, Michigan, Mississippi, Nebraska
2025-02-13
Recruiting
BOOM-IBD2 Pivotal Clinical Trial
NCT06571669Ulcerative Colitis, Inflammatory Bowel Diseases
Boomerang Medical
Not applicable
137
California, Kansas, Minnesota, Mississippi, Missouri, Nevada, New York, North Carolina
2025-01-31
Recruiting
Tissue Repair Gel in Venous Leg Ulcers (US)
NCT06707090Venous Leg Ulcer, Venous Ulcer, Venous Stasis Ulcer, Venous Stasis
DrugGlucoprime
TR Therapeutics
Phase 3
312
Arizona, California, Florida, Illinois, Louisiana, Mississippi, New York, North Carolina
2025-01-28
Recruiting
Laminate Medical Technologies
Not applicable
300
California, Florida, Georgia, Massachusetts, Mississippi, Nevada, South Carolina, Texas
2025-01-13
Active, closed
Coherus Oncology, Inc.
Phase 2
72
Arizona, California, Florida, Georgia, Idaho, Kansas, Kentucky, Mississippi
2024-12-20
Recruiting
The PERSEVERE Study
NCT06588634Pulmonary Embolism, Pulmonary Thromboembolism
Inari Medical
Not applicable
200
Connecticut, Florida, Georgia, Mississippi, New Jersey, New York, Ohio, Pennsylvania
2024-12-16
Active, closed
AbbVie
Phase 2
185
California, Florida, Georgia, Mississippi, North Carolina, Texas
2024-12-13
Active, closed
Sanofi
Phase 2
260
Arizona, Connecticut, Florida, Illinois, Michigan, Mississippi, Nevada, New York
2024-12-10
Recruiting
Intra-Cellular Therapies, Inc.
Phase 2
570
Alabama, Arkansas, California, Connecticut, Florida, Georgia, Mississippi, New York
2024-11-21
Recruiting
E-Star BioTech, LLC
Phase 2
120
Arkansas, California, Florida, Georgia, Illinois, Michigan, Mississippi, New York
2024-11-17
Recruiting
Aventix Medical Inc.
Not applicable
30
Colorado, Mississippi, Texas
2024-11-15
By invitation
Xeltis Hemodialysis Access Graft (aXess) US Study
NCT06494631End Stage Renal Disease
Xeltis
Not applicable
140
Arizona, Florida, Massachusetts, Mississippi, North Carolina, Texas
2024-11-11
Active, closed
MBX Biosciences
Phase 2
60
Florida, Georgia, Mississippi, Missouri, Nevada, New York, Ohio, Texas
2024-10-31
Active, closed
Eli Lilly and Company
Phase 2
252
Alabama, California, Florida, Hawaii, Illinois, Mississippi, Pennsylvania, Washington
2024-10-21
Recruiting
Thrombolex, Inc.
Not applicable
500
Arizona, Florida, Georgia, Illinois, Indiana, Massachusetts, Mississippi, New Hampshire
2024-10-17
Recruiting
Xencor, Inc.
Phase 1/2
270
Arizona, California, Florida, Kentucky, Mississippi, New York, North Carolina, Ohio
2024-10-10
Recruiting
BeOne Medicines
Phase 1
310
Arizona, California, Colorado, Connecticut, Illinois, Kansas, Mississippi, New Jersey
2024-10-03
Active, closed
Eisai Inc.
Phase 2
105
Arizona, Connecticut, Florida, Georgia, Mississippi, Missouri, Pennsylvania, Tennessee
2024-09-30
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
406
Arizona, California, Connecticut, Florida, Georgia, Massachusetts, Michigan, Mississippi
2024-09-26
Recruiting
ModernaTX, Inc.
Phase 4
1,144
Georgia, Louisiana, Mississippi, Nebraska, Virginia
2024-09-09
Active, closed
Janssen Pharmaceutica N.V., Belgium
Phase 2
55
Arizona, California, Connecticut, Florida, Illinois, Michigan, Mississippi, New Jersey
2024-07-22
Recruiting
Sanofi
Phase 4
20
California, Mississippi
2024-03-01
Active, closed
Acumen Pharmaceuticals
Phase 2
542
California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Massachusetts, Mississippi
2024-02-29
Recruiting
Natera, Inc.
Observational
4,000
Arizona, California, Florida, Mississippi, New Jersey, New York, Texas
2024-01-25
Active, closed
Bolt Medical
Not applicable
936
California, Colorado, Florida, Georgia, Massachusetts, Michigan, Minnesota, Mississippi
2024-01-19
Recruiting
Regeneron Pharmaceuticals
Phase 3
580
California, Florida, Indiana, Mississippi, New Hampshire, New York, Wisconsin
2023-12-28
Recruiting
Regeneron Pharmaceuticals
Phase 3
822
Arizona, California, Indiana, Massachusetts, Michigan, Mississippi, New York, North Carolina
2023-12-12
Active, closed
OncoC4, Inc.
Phase 1/2
148
California, Colorado, Florida, Georgia, Maryland, Massachusetts, Mississippi, Nebraska
2023-12-11
Active, closed
Gilead Sciences
Phase 2
176
Arizona, California, Florida, Michigan, Minnesota, Mississippi, Missouri, New York
2023-12-05
Active, closed
AltruBio Inc.
Phase 2
50
California, Colorado, Florida, Indiana, Kentucky, Louisiana, Mississippi, New York
2023-12-04
Active, closed
Merck Sharp & Dohme LLC
Phase 3
556
California, Florida, Georgia, Michigan, Minnesota, Mississippi, Nebraska, New Jersey
2023-11-12
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
500
Arizona, California, Florida, Georgia, Illinois, Louisiana, Michigan, Mississippi
2023-08-28
Active, closed
Ocugen
Phase 2/3
51
Arizona, California, Florida, Indiana, Massachusetts, Mississippi, Missouri, North Carolina
2023-08-25
Recruiting
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
NCT05677100Heart Failure, Cardiorenal Syndrome, Cardio-Renal Syndrome, ADHF
Procyrion
Not applicable
320
Arizona, California, Florida, Georgia, Illinois, Kansas, Michigan, Mississippi
2023-08-23
Active, closed
Regeneron Pharmaceuticals
Phase 2/3
160
Arizona, California, Colorado, Connecticut, Florida, Illinois, Louisiana, Mississippi
2023-08-08
Recruiting
Merck Sharp & Dohme LLC
Phase 3
735
Arkansas, California, Florida, Indiana, Maryland, Mississippi, Missouri, Montana
2023-08-08
Recruiting
Encore PFO Closure Device - The PerFOrm Trial
NCT05537753Patent Foramen Ovale, Cryptogenic Stroke
Encore Medical Inc.
Not applicable
500
Arkansas, California, Florida, Iowa, Kansas, Mississippi, Nebraska, South Carolina
2023-07-12
Active, closed
Regeneron Pharmaceuticals
Phase 2/3
149
Arizona, California, Connecticut, Florida, Illinois, Louisiana, Mississippi, Missouri
2023-06-30
Active, closed
Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty)
NCT05787821Knee Pain Chronic, Osteoarthritis, Knee, Rheumatoid Arthritis, Traumatic Arthritis
Zimmer Biomet
Observational
760
Colorado, Florida, Georgia, Kentucky, Michigan, Minnesota, Mississippi, New Mexico
2023-06-28
Recruiting
GEn1E Lifesciences
Phase 2
52
District of Columbia, Kansas, Maryland, Mississippi, Missouri, New Jersey, New York, Ohio
2023-04-04
Active, closed
Merck Sharp & Dohme LLC
Phase 3
300
Arkansas, Florida, Mississippi, Washington
2023-03-16
Active, closed
Camera Qualification Study
NCT05808699Diabetic Retinopathy
Digital Diagnostics, Inc.
Observational
626
California, Florida, Mississippi, Montana, North Dakota, Texas
2023-03-03
Active, closed
Pfizer
Phase 3
624
California, Connecticut, Florida, Illinois, Kentucky, Louisiana, Mississippi, Missouri
2023-03-03
Recruiting
BeiGene
Observational
111
Alabama, California, Mississippi, Nevada
2023-03-03
Active, closed
Ocugen
Phase 1/2
60
Arizona, Florida, Indiana, Mississippi, Missouri, New Jersey, North Carolina, Pennsylvania
2023-02-23
Active, closed
Merck Sharp & Dohme LLC
Phase 3
377
Arizona, Florida, Illinois, Indiana, Kentucky, Mississippi, Missouri
2023-02-14
Recruiting
Regeneron Pharmaceuticals
Phase 2
120
Arizona, California, Colorado, Florida, Indiana, Louisiana, Maryland, Mississippi
2023-02-09
Active, closed
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
NCT05527184Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
DrugIMGN151
AbbVie
Phase 1
256
Alabama, California, Colorado, Florida, Illinois, Massachusetts, Michigan, Mississippi
2023-01-11
Recruiting
Pfizer
Phase 3
173
California, Florida, Indiana, Mississippi, New York, Pennsylvania, Washington
2022-12-28
Active, closed
Shanton Pharma Pte. Ltd.
Phase 2
87
California, Colorado, Florida, Idaho, Maryland, Mississippi, North Carolina, Texas
2022-12-12
Active, closed
Genentech, Inc.
Phase 1
151
Arizona, Arkansas, California, Florida, Maryland, Michigan, Minnesota, Mississippi
2022-12-08
Active, closed
Abbott Atrial Fibrillation Post Approval Study
NCT05434650Atrial Arrhythmia, Atrium; Fibrillation, Atrial Tachycardia
Abbott Medical Devices
Observational
200
Alabama, Arkansas, California, Georgia, Louisiana, Massachusetts, Michigan, Mississippi
2022-10-21
Recruiting
Pfizer
Phase 2/3
389
Alabama, Connecticut, Florida, Georgia, Illinois, Louisiana, Michigan, Mississippi
2022-09-22
Active, closed
AstraZeneca
Phase 3
594
Alabama, Arizona, California, Florida, Georgia, Indiana, Maryland, Mississippi
2022-09-15
Active, closed
Adverum Biotechnologies, Inc.
Phase 2
69
Arizona, California, Colorado, Connecticut, Florida, Hawaii, Michigan, Mississippi
2022-08-23
Recruiting
Janssen Research & Development, LLC
Phase 1/2
225
Alabama, California, District of Columbia, Florida, Maryland, Michigan, Mississippi, New York
2022-07-29
Active, closed
Sanofi
Phase 3
531
Colorado, Florida, Mississippi, New Jersey, New York, North Carolina, Ohio, South Carolina
2022-06-23
Recruiting
AbbVie
Phase 2
75
California, Georgia, Iowa, Massachusetts, Michigan, Minnesota, Mississippi, New Jersey
2022-03-28
Active, closed
Merck Sharp & Dohme LLC
Phase 3
460
Alabama, California, Florida, Indiana, Massachusetts, Michigan, Mississippi, Pennsylvania
2022-03-24
Active, closed
Laekna Limited
Phase 3
256
California, Georgia, Iowa, Mississippi, Vermont, Virginia
2022-02-18
Active, closed
BioMarin Pharmaceutical
Phase 1/2
44
Alabama, Arizona, California, Colorado, Kansas, Maryland, Mississippi, Missouri
2022-02-15
Recruiting
Novartis Pharmaceuticals
Phase 1/2
34
Indiana, Massachusetts, Mississippi, New York, Ohio, Pennsylvania, Texas, Utah
2021-12-27
Active, closed
Janssen Research & Development, LLC
Phase 3
776
Alabama, Arizona, California, Colorado, Florida, Georgia, Mississippi, Nebraska
2021-11-17
Recruiting
STRIVE Post-Market Registry Study
NCT04302272Emphysema
Olympus Corporation of the Americas
Observational
150
Arizona, California, Florida, Illinois, Louisiana, Maryland, Massachusetts, Mississippi
2021-10-09
Active, closed
Avenir Complete Post-Market Clinical Follow-Up Study
NCT04731077Osteoarthritis, Hip, Avascular Necrosis of Hip, Avascular Necrosis of the Femoral Head, Post-traumatic; Arthrosis
Zimmer Biomet
Not applicable
275
Mississippi, Missouri, Oregon
2021-09-27
Active, closed
Orthofix Inc.
Observational
2,000
California, Louisiana, Mississippi, North Carolina, Rhode Island, Utah, Virginia
2021-09-15
Recruiting
Zimmer Biomet Shoulder Arthroplasty PMCF
NCT04984291Shoulder Fractures, Shoulder Arthritis, Shoulder Osteoarthritis, Shoulder Deformity
Zimmer Biomet
Not applicable
584
California, Colorado, Illinois, Kentucky, Michigan, Minnesota, Mississippi, Missouri
2021-07-28
Active, closed
Persona Ti-Nidium Post-Market Clinical Follow-up
NCT04817969Knee Pain Chronic, Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis
Zimmer Biomet
Not applicable
240
Colorado, Maryland, Mississippi, New Mexico, North Carolina, Pennsylvania, South Dakota
2021-06-01
Active, closed
HUYABIO International, LLC.
Phase 2
150
Florida, Illinois, Mississippi, Texas
2021-06-01
Active, closed
Editas Medicine, Inc.
Phase 1/2
45
California, Colorado, Connecticut, Florida, Georgia, Illinois, Mississippi, New Jersey
2021-05-04
Active, closed
Hoffmann-La Roche
Phase 3
270
Alabama, California, Florida, Maryland, Massachusetts, Mississippi, New Jersey, New York
2021-02-23
Recruiting
Upsher-Smith Laboratories
Phase 4
132
Alabama, California, Colorado, Connecticut, Florida, Michigan, Mississippi, Missouri
2021-02-19
Active, closed
Mirum Pharmaceuticals, Inc.
Phase 2
182
California, Colorado, District of Columbia, Florida, Massachusetts, Michigan, Minnesota, Mississippi
2020-12-18
Active, closed
Artoss Inc.
Observational
330
Arizona, California, Connecticut, Maryland, Mississippi
2020-08-03
Active, closed
Apifix
Not applicable
201
California, Florida, Georgia, Indiana, Kansas, Minnesota, Mississippi, Missouri
2020-05-31
Active, closed
BeOne Medicines
Phase 3
955
Arizona, Arkansas, Colorado, Florida, Massachusetts, Michigan, Minnesota, Mississippi
2020-01-16
Active, closed
Abbott Medical Devices
Observational
20
California, Florida, Georgia, Mississippi, Ohio, Texas
2019-10-24
Active, closed
Applied Therapeutics, Inc.
Phase 3
675
California, Florida, Illinois, Massachusetts, Mississippi, Missouri, New York, Ohio
2019-09-20
Active, closed
Pfizer
Phase 3
51
California, Colorado, Indiana, Mississippi, Pennsylvania
2019-07-29
Recruiting
Oxford BioTherapeutics Ltd
Phase 1
200
Arizona, California, Florida, Iowa, Kentucky, Mississippi, New Mexico, New York
2019-07-25
Active, closed
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
NCT04008797Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms
DrugsE7386·Doxorubicin·Lenvatinib·Paclitaxel
Eisai Inc.
Phase 1/2
301
Arkansas, California, Colorado, Florida, Louisiana, Mississippi, Missouri, New York
2019-07-11
Recruiting
Gedeon Richter Plc.
Phase 3
330
California, Georgia, Michigan, Mississippi, New York, Ohio, Texas
2019-06-06
Active, closed
Spark Therapeutics, Inc.
Observational
29
Massachusetts, Mississippi, Missouri, Oregon, Pennsylvania, Virginia
2018-08-14
Recruiting
Astellas Institute for Regenerative Medicine
Phase 1
42
Arizona, California, Florida, Georgia, Illinois, Massachusetts, Michigan, Mississippi
2018-07-13
Active, closed
DePuy Orthopaedics
Not applicable
400
California, Colorado, Connecticut, Florida, Kentucky, Mississippi, New Hampshire, New Jersey
2017-09-19
Active, closed
The Chocolate Touch Study
NCT02924857Peripheral Artery Disease (PAD), Ischemia, Intermittent Claudication
TriReme Medical, LLC
Not applicable
333
Florida, Georgia, Louisiana, Michigan, Mississippi, Missouri, New York, Ohio
2017-07-26
Active, closed
DePuy Orthopaedics
Not applicable
400
California, Colorado, Connecticut, Florida, Kentucky, Mississippi, Missouri, New Hampshire
2017-05-30
Rows per page Showing 1–136 of 136
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-usa/state/mississippi

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,132 studies in total at the last sync on 11 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 136 of those studies with a site in Mississippi.

How many clinical trials are recruiting in Mississippi?

77 of the 136 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:16 UTC sync. A further 2 have not yet opened recruitment, 56 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Mississippi), 136 studies
PhaseStudiesRecruitingShare
Phase 3412430.1%
Phase 2331724.3%
Not applicable271819.9%
Observational1148.1%
Phase 1/2946.6%
Phase 2/3634.4%
Phase 1533.7%
Phase 4442.9%

Most active sponsors

Lead sponsors with the most studies (Mississippi)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC72
Pfizer53
Regeneron Pharmaceuticals53
AbbVie42
Zimmer Biomet41
Bristol-Myers Squibb33
NuScience Medical Biologics, LLC33
Sanofi31
Abbott Medical Devices20
AstraZeneca21
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.